On Tuesday morning, AstraZeneca's stock experienced a moderate increase due to stronger-than-anticipated sales and profits in the fourth quarter. The company reconfirmed its long-term outlook, projecting a revenue of $80 billion by 2030, prior to an anticipated period of significant growth in 2026.